Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI-2852 |
| Synonyms | |
| Therapy Description |
BI-2852 is a KRAS inhibitor that binds to the pocket between the switch I and II regions and inhibits interaction with GEF, GAP, and effector proteins, potentially blocking activation of downstream signaling and inhibiting cell proliferation (PMID: 31332011). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI-2852 | BI 2852|BI2852 | KRAS Inhibitor 30 | BI-2852 is a KRAS inhibitor that binds to the pocket between the switch I and II regions and inhibits interaction with GEF, GAP, and effector proteins, potentially blocking activation of downstream signaling and inhibiting cell proliferation (PMID: 31332011). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|